论文部分内容阅读
虽然曲妥珠单抗可以明显改善HER-2阳性乳腺癌患者的预后,但大多数患者病情最终会出现进展,而HER-2高水平表达患者对曲妥珠单抗初始治疗也不敏感,HER-2阴性患者也没有合适的靶向治疗策略。新的靶向药物是未来研究的方向。
Although trastuzumab can significantly improve the prognosis of patients with HER-2-positive breast cancer, progression is most likely to occur in most patients, whereas patients with high HER-2 expression are not sensitive to initial treatment with trastuzumab. HER -2 negative patients also did not have a suitable targeted therapy strategy. The new targeted drug is the future research direction.